EVO vs. CPRX, AMPH, AGIO, KROS, GLPG, DCPH, SNDX, AMRX, NAMS, and ARDX
Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Catalyst Pharmaceuticals (CPRX), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), Keros Therapeutics (KROS), Galapagos (GLPG), Deciphera Pharmaceuticals (DCPH), Syndax Pharmaceuticals (SNDX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
Catalyst Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Evotec. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 4 mentions for Evotec. Evotec's average media sentiment score of 0.97 beat Catalyst Pharmaceuticals' score of 0.64 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.
79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Catalyst Pharmaceuticals has higher earnings, but lower revenue than Evotec.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Catalyst Pharmaceuticals' net margin of 0.00%. Evotec's return on equity of 25.08% beat Catalyst Pharmaceuticals' return on equity.
Catalyst Pharmaceuticals currently has a consensus price target of $26.71, suggesting a potential upside of 62.00%. Evotec has a consensus price target of $11.00, suggesting a potential upside of 109.52%. Given Catalyst Pharmaceuticals' higher possible upside, analysts clearly believe Evotec is more favorable than Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals received 480 more outperform votes than Evotec when rated by MarketBeat users. However, 75.00% of users gave Evotec an outperform vote while only 74.31% of users gave Catalyst Pharmaceuticals an outperform vote.
Summary
Catalyst Pharmaceuticals beats Evotec on 11 of the 15 factors compared between the two stocks.
Get Evotec News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
